U3 Pharma GmbH Report issue

For profit Phase 1
Founded: Planegg Germany (2001)
Status: Acquired by Daiichi Sankyo (2008)

Organization Overview

First Clinical Trial
2008
NCT00730470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (1)

patritumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1